The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses

ABSTRACT Zika virus (ZIKV) is a mosquito-borne pathogen with public health importance due to the high risk of its mosquito vector dissemination and the severe neurological and teratogenic sequelae associated with infection. Vaccines with broad immune specificity and control against this re-emerging virus are needed. Here, we described that mice immunized with a priming dose of a DNA plasmid mammalian expression vector encoding ZIKV prM-E antigens (DNA-ZIKV) followed by a booster dose of a modified vaccinia virus Ankara (MVA) vector expressing the same prM-E ZIKV antigens (MVA-ZIKV) induced broad, polyfunctional and long-lasting ZIKV-specific CD4+ and CD8+ T-cell immune responses, with high levels of CD4+ T follicular helper cells, together with the induction of neutralizing antibodies. All those immune parameters were significantly stronger in the heterologous DNA-ZIKV/MVA-ZIKV immunization group compared to the homologous prime/boost immunizations regimens. Collectively, these results provided an optimized immunization protocol able to induce high levels of ZIKV-specific T-cell responses, as well as neutralizing antibodies and reinforce the combined use of DNA-based vectors and MVA-ZIKV as promising prophylactic vaccination schedule against ZIKV.

[1]  C. del Fresno,et al.  COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice , 2021, Journal of Virology.

[2]  Zhengrong Hu,et al.  A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques , 2021, Emerging microbes & infections.

[3]  Jialu Zhang,et al.  Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates , 2021, Emerging microbes & infections.

[4]  S. Vasudevan,et al.  Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection , 2020, EBioMedicine.

[5]  S. Buus,et al.  Effector CD8 T Cell-Dependent Zika Virus Control in the CNS: A Matter of Time and Numbers , 2020, Frontiers in Immunology.

[6]  A. Agarwal,et al.  The expanding arms of Zika virus: An updated review with recent Indian outbreaks , 2020, Reviews in medical virology.

[7]  Colin J. Carlson,et al.  Warming temperatures could expose more than 1.3 billion new people to Zika virus risk by 2050 , 2020, medRxiv.

[8]  Bikash R. Sahoo,et al.  Current Status of Zika Virus Vaccines: Successes and Challenges , 2020, Vaccines.

[9]  M. Roberts,et al.  Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus , 2020, Vaccines.

[10]  Jufang Huang,et al.  Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. , 2020, Virology.

[11]  G. Pantaleo,et al.  Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses , 2019, Front. Immunol..

[12]  C. Sorzano,et al.  An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design , 2019, Vaccines.

[13]  Young Chan Kim,et al.  Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers , 2019, Pathogens.

[14]  M. Richer,et al.  Protective to a T: The Role of T Cells during Zika Virus Infection , 2019, Cells.

[15]  J. Brien,et al.  Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection , 2019, Front. Immunol..

[16]  Yang Yang,et al.  Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. , 2019, Vaccine.

[17]  C. Sorzano,et al.  Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV , 2019, Journal of Virology.

[18]  M. Diamond,et al.  Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine , 2018, Scientific Reports.

[19]  G. Gabriel,et al.  A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model , 2018, Journal of Virology.

[20]  J. Saiz,et al.  A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice , 2018, Scientific Reports.

[21]  J. Valverde,et al.  Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B , 2018, Viruses.

[22]  C. Yip,et al.  Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models , 2018, The Journal of infectious diseases.

[23]  S. Shresta,et al.  Immune Response to Dengue and Zika. , 2018, Annual review of immunology.

[24]  A. Suhrbier,et al.  A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses , 2018, Nature Communications.

[25]  A. Brun,et al.  Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination , 2018, Veterinary Research.

[26]  G. Sutter,et al.  Chapter Five Modified Vaccinia Virus Ankara History, Value in Basic Research, and Current Perspectives for Vaccine Development , 2017, Advances in Virus Research.

[27]  J. Mascola,et al.  Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials , 2017, The Lancet.

[28]  M. Diamond,et al.  Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge , 2017, Nature Communications.

[29]  A. Brault,et al.  A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model , 2017, Scientific Reports.

[30]  S. Trottier,et al.  Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. , 2017, The New England journal of medicine.

[31]  G. Barber,et al.  Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity , 2017, The Journal of Immunology.

[32]  J. Saiz,et al.  Zika virus infection confers protection against West Nile virus challenge in mice , 2017, Emerging Microbes &Infections.

[33]  B. Cissé,et al.  Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal , 2016, PloS one.

[34]  J. Mascola,et al.  Rapid development of a DNA vaccine for Zika virus , 2016, Science.

[35]  Jessica Jimenez,et al.  Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys , 2016, Science.

[36]  Richard G. Jarman,et al.  Vaccine Protection Against Zika Virus from Brazil , 2016, Nature.

[37]  S. McCormack,et al.  Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial , 2016, PloS one.

[38]  D. Montefiori,et al.  Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap , 2016, Clinical and Vaccine Immunology.

[39]  J. Saiz,et al.  Zika Virus: the Latest Newcomer , 2016, Front. Microbiol..

[40]  Andrew J. Pollard,et al.  Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults , 2015, Science Translational Medicine.

[41]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[42]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[43]  S. Crotty.  T follicular helper cell differentiation, function, and roles in disease. , 2014, Immunity.

[44]  J. Saiz,et al.  Protection of a Single Dose West Nile Virus Recombinant Subviral Particle Vaccine against Lineage 1 or 2 Strains and Analysis of the Cross-Reactivity with Usutu Virus , 2014, PloS one.

[45]  J. Saiz,et al.  The Composition of West Nile Virus Lipid Envelope Unveils a Role of Sphingolipid Metabolism in Flavivirus Biogenesis , 2014, Journal of Virology.

[46]  C. Sorzano,et al.  Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens , 2014, Journal of Virology.

[47]  J. Saiz,et al.  Infection with Usutu Virus Induces an Autophagic Response in Mammalian Cells , 2013, PLoS neglected tropical diseases.

[48]  G. Sutter,et al.  Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. , 2013, Vaccine.

[49]  C. Sorzano,et al.  Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways , 2013, PloS one.

[50]  C. Sorzano,et al.  A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses , 2011, PloS one.

[51]  Felipe García,et al.  The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens , 2011, Journal of Virology.

[52]  C. Sorzano,et al.  Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions , 2010, PloS one.

[53]  S. Akira,et al.  Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome , 2009, PLoS pathogens.

[54]  R. Locksley,et al.  Cytokine-secreting follicular T cells shape the antibody repertoire , 2009, Nature Immunology.

[55]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[56]  A. Helenius,et al.  Intracellular Assembly and Secretion of Recombinant Subviral Particles from Tick-Borne Encephalitis Virus , 2003, Journal of Virology.

[57]  B. Moss,et al.  Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting , 2003, Journal of Virology.

[58]  John H. Reif,et al.  Successes and challenges , 2021, Strategic Community Partnerships, Philanthropy, and Nongovernmental Organization.

[59]  P. Palese,et al.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Pamela G. Guren,et al.  Candidates , 1982, Otolaryngology–Head and Neck Surgery.